Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias? Source: Eur Respir J, 57 (3) 2004562; 10.1183/13993003.04562-2020 Year: 2021
Historical eye on idiopathic pulmonary fibrosis: redefining the mortality scenario. Source: Virtual Congress 2020 – New clinical insights into idiopathic pulmonary fibrosis Year: 2020
Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue Source: Eur Respir Rev, 28 (153) 190044; 10.1183/16000617.0044-2019 Year: 2019
The value of the surprise question to predict mortality in idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – What is hot in idiopathic pulmonary fibrosis? Year: 2020
Malnutrition in idiopathic pulmonary fibrosis: the great forgotten comorbidity! Source: Eur Respir J, 53 (5) 1900418; 10.1183/13993003.00418-2019 Year: 2019
Idiopathic pulmonary fibrosis: time for greater expectations? Source: Eur Respir J, 52 (2) 1801312; 10.1183/13993003.01312-2018 Year: 2018
The therapy of idiopathic pulmonary fibrosis: what is next? Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019 Year: 2019
Early COVID-19 lockdown in Greece and idiopathic pulmonary fibrosis: a beneficial “impact” beyond any expectation Source: Eur Respir J, 57 (3) 2003111; 10.1183/13993003.03111-2020 Year: 2021
Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation Source: Eur Respir J 2012; 40: 794-795 Year: 2012
Communicating with patients with idiopathic pulmonary fibrosis: can we do it better? Source: ERJ Open Res, 8 (1) 00422-2021; 10.1183/23120541.00422-2021 Year: 2022
Reply to: Malnutrition in idiopathic pulmonary fibrosis: the great forgotten comorbidity! Source: Eur Respir J, 53 (5) 1900615; 10.1183/13993003.00615-2019 Year: 2019
Idiopathic pulmonary fibrosis: tracking the true occurrence is challenging Source: Eur Respir J 2015; 46: 604-606 Year: 2015
Mortality outcomes in patients with idiopathic pulmonary fibrosis treated with antifibrotics: a real world study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021
Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015
A prothrombotic state is associated with increased mortality in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013
A global registry for idiopathic pulmonary fibrosis: the time is now Source: Eur Respir J 2014; 44: 273-276 Year: 2014
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential Source: Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017 Year: 2017
Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease Source: Eur Respir Rev, 27 (150) 180110; 10.1183/16000617.0110-2018 Year: 2018
Severe idiopathic pulmonary fibrosis: what can be done? Source: Eur Respir Rev, 26 (145) 170047; 10.1183/16000617.0047-2017 Year: 2017
Are the gains due to pulmonary rehabilitation in idiopathic pulmonary fibrosis and other interstitial lung diseases the same? Source: Virtual Congress 2020 – The multiple facets of pulmonary rehabilitation and chronic respiratory care Year: 2020